Skip to main content
. Author manuscript; available in PMC: 2012 Dec 1.
Published in final edited form as: JACC Cardiovasc Imaging. 2011 Dec;4(12):1284–1293. doi: 10.1016/j.jcmg.2011.09.013

Figure 2. Impact of MSC Therapy assessed by MDCT.

Figure 2

(A–D) All placebo animals (n=8) showed an increase in infarct size (A) and infarct volume (C) at week 24, while intra-myocardial delivery of MSCs reduced infarct size (B) and stabilized infarct volume (D) in all treated animals (n=11).(E, F) LVEF is decreased at week 24 in placebo animals, while it increases in most MSC treated animals; however, in 2 animals the treatment failed to improve LVEF.